CUSIP No. 746927102 SCHEDULE 13D/A Page 1 of 8

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D/A

 

Under the Securities Exchange Act of 1934

 

(Amendment No. 2)

 

 

QLT Inc.

 

(Name of Issuer)

 

Common Shares, no par value

 

(Title of Class of Securities)

 

746927102 

 

(CUSIP Number)

 

James E. Dawson, Esq., Nutter, McClennen & Fish LLP

155 Seaport Blvd, Boston, MA 02210

 

(Name, Address and Telephone Number of Person Authorized to Receive Notices and

Communications)

 

July 11, 2014

 

(Date of Event Which Requires Filing of This Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box . ¨

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 
 

CUSIP No. 746927102 SCHEDULE 13D/A Page 2 of 8

 

 

(1) Names of reporting persons

NB Public Equity K/S

 

(2) Check the appropriate box if a member of a group (see instructions)

(a) ¨

(b) ¨

 

(3) SEC use only

 

(4) Source of Funds (See Instructions)

00

 

(5) Check if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e) ¨

 

(6) Citizenship or place of organization

Denmark

 

 

 

Number of shares beneficially owned by each reporting person with:

(7) Sole voting power:

0

 

(8) Shared voting power:

6,447,626

 

(9) Sole dispositive power:

0

 

(10) Shared dispositive power:

6,447,626

 

(11) Aggregate amount beneficially owned by each reporting person:

6,447,626

 

(12) Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨

 

(13) Percent of class represented by amount in Row 11:

12.6%

 

(14) Type of reporting person (see instructions):

PN

 

 

 
 

CUSIP No. 746927102 SCHEDULE 13D/A Page 3 of 8

 

 

(1) Names of reporting persons

NB Public Equity Komplementar ApS

 

(2) Check the appropriate box if a member of a group (see instructions)

(a) ¨

(b) ¨

 

(3) SEC use only

 

(4) Source of Funds (See Instructions)

00

 

(5) Check if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e) ¨

 

(6) Citizenship or place of organization

Denmark

 

 

 

Number of shares beneficially owned by each reporting person with:

(7) Sole voting power:

0

 

(8) Shared voting power:

6,447,626

 

(9) Sole dispositive power:

0

 

(10) Shared dispositive power:

6,447,626

 

(11) Aggregate amount beneficially owned by each reporting person:

6,447,626

 

(12) Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨

 

(13) Percent of class represented by amount in Row 11:

12.6%

 

(14) Type of reporting person (see instructions):

PN

 

 

 

 
 

CUSIP No. 746927102 SCHEDULE 13D/A Page 4 of 8

 

 

(1) Names of reporting persons

Cora Madsen

 

(2) Check the appropriate box if a member of a group (see instructions)

(a) ¨
(b) ¨

 

(3) SEC use only

 

(4) Source of Funds (See Instructions)

00

 

(5) Check if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e) ¨

   

(6) Citizenship or place of organization

United States

 

 

 

Number of shares beneficially owned by each reporting person with:

(7) Sole voting power:

0

 

(8) Shared voting power:

6,447,626

 

(9) Sole dispositive power:

0

 

(10) Shared dispositive power:

6,447,626

 

(11) Aggregate amount beneficially owned by each reporting person:

6,447,626

 

(12) Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨

 

(13) Percent of class represented by amount in Row 11:

12.6%

 

(14) Type of reporting person (see instructions):

IN

 

 

 

 
 

CUSIP No. 746927102 SCHEDULE 13D/A Page 5 of 8

 

 

(1) Names of reporting persons

Florian Schönharting

 

(2) Check the appropriate box if a member of a group (see instructions)

(a) ¨
(b) ¨

 

(3) SEC use only

  

(4) Source of Funds (See Instructions)

00

 

(5) Check if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e) ¨

  

(6) Citizenship or place of organization

Denmark

 

 

 

Number of shares beneficially owned by each reporting person with:

(7) Sole voting power:

0

 

(8) Shared voting power:

6,447,626

 

(9) Sole dispositive power:

0

 

(10) Shared dispositive power:

6,447,626

 

(11) Aggregate amount beneficially owned by each reporting person:

6,447,626

 

(12) Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨

  

(13) Percent of class represented by amount in Row 11:

12.6%

 

(14) Type of reporting person (see instructions):

IN

 

 
 

CUSIP No. 746927102 SCHEDULE 13D/A Page 6 of 8

 

 

This Amendment No. 2 amends and supplements, as set forth below, the information contained in Item 5 of the Schedule 13D that was originally filed with the Securities and Exchange Commission by NB Public Equity K/S, NB Public Equity Komplementar ApS, Cora Madsen and Florian Schönharting (the “Reporting Persons”) on May 22, 2012, as amended by Amendment No. 1, filed with the SEC on June 5, 2012 (together, the “Schedule 13D”). Capitalized terms used but not otherwise defined in this Amendment No. 2 are used with the meanings ascribed to them in the Schedule 13D. Except as amended by this Amendment No. 2, all information contained in the Schedule 13D is, after reasonable inquiry and to the best of the Reporting Persons’ knowledge and belief, true, complete and correct as of the date of this Amendment No. 2.

 

Item 5. Interest in Securities of the Company.

 

Item 5 of the Schedule 13D is hereby revised to state as follows:

 

(a) The Fund is the beneficial owner of an aggregate of 6,447,626 (1) shares of Common Stock, representing approximately 12.6% (2) of the total issued and outstanding shares of Common Stock.

 

The General Partner is the beneficial owner of an aggregate of 6,447,626 (3) shares of Common Stock, representing approximately 12.6% (2) of the total issued and outstanding shares of Common Stock.

 

Cora Madsen is the beneficial owner of an aggregate of 6,447,626 (4) shares of Common Stock, representing approximately 12.6% (2) of the total issued and outstanding shares of Common Stock.

 

Florian Schönharting is the beneficial owner of an aggregate of 6,447,626 (5) shares of Common Stock, representing approximately 12.6% (2) of the total issued and outstanding shares of Common Stock.

 

(b) Each of the Reporting Persons has the sole power to vote or direct the vote of 0 shares and the shared power to vote or direct the vote of 6,447,626 shares of Common Stock. Each of the Reporting Persons has the sole power to dispose or to direct the disposition of 0 shares, and the shared power to dispose or direct the disposition of 6,447,626 shares of Common Stock.

 

(c) On July 11, 2014, the Fund sold 1,000,000 shares of Common Stock in the open market at a weighted average price per share equal to $5.80. No other transactions in the Common Stock were effected by the Reporting Persons within the past 60 days.

 

(d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the shares owned by it individually.

 

(e) Not applicable.

 


( 1 ) The Fund directly owns 6,447,626 shares.

 

(2) Based on 51,081,878 shares of Common Stock outstanding as of April 23, 2014.

 

(3) The General Partner has no ownership share in the Fund, but is entitled to a management fee for the services provided to the Fund. By reason of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (“Rule 13d-3”), the General Partner may be deemed to be the beneficial owner of the securities held by the Fund.

 

 

 
 

CUSIP No. 746927102 SCHEDULE 13D/A Page 7 of 8

 

 

(4) Cora Madsen is a director of the General Partner and in this capacity has the legal power to direct the voting or disposition of the Common Stock beneficially owned by the Fund. Therefore, by reason of Rule 13d-3, Ms. Madsen may be deemed to be the beneficial owner of securities held by the Fund. Ms. Madsen has no ownership interest, either direct or indirect, in the General Partner.

 

(5) Florian Schönharting is a director of Nordic Biotech Advisors ApS, which owns 100% of the shares of the General Partner, and is an indirect investor in a limited partner of the Fund. As such, he may be deemed under Rule 13d-3 to be a beneficial owner of the securities held by the Fund.

 

 
 

CUSIP No. 746927102 SCHEDULE 13D/A Page 8 of 8

 

 

SIGNATURE

 

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

 

Dated: July 15, 2014

 

  NB PUBLIC EQUITY K/S
         
  By: NB PUBLIC EQUITY KOMPLEMENTAR ApS,
    its general partner
         
    By: /s/ Cora Madsen*  
    Name: Cora Madsen
    Title: Managing Director
         
  NB PUBLIC EQUITY KOMPLEMENTAR ApS
   
  By: /s/ Cora Madsen*  
    Name: Cora Madsen
    Title: Managing Director
         
         
  /s/ Cora Madsen *  
  Cora Madsen  
         
         
  /s/ Florian Schönharting*  
  Florian Schönharting  
         
         
  *By: /s/ James E. Dawson  
  James E. Dawson, as attorney-in-fact  

 

 

 

 

 

Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Novelion Therapeutics Charts.
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Novelion Therapeutics Charts.